Cannapharmarx Stock Net Income
| CPMD Stock | USD 0 0.0004 10.26% |
As of the 6th of February, CannaPharmaRx shows the Mean Deviation of 10.06, downside deviation of 18.02, and Risk Adjusted Performance of 0.0587. CannaPharmaRx technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CannaPharmaRx information ratio and the relationship between the maximum drawdown and skewness to decide if CannaPharmaRx is priced correctly, providing market reflects its regular price of 0.0035 per share. As CannaPharmaRx appears to be a penny stock we also recommend to validate its total risk alpha numbers.
CannaPharmaRx's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CannaPharmaRx's valuation are provided below:CannaPharmaRx does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. CannaPharmaRx |
CannaPharmaRx 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CannaPharmaRx's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CannaPharmaRx.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in CannaPharmaRx on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding CannaPharmaRx or generate 0.0% return on investment in CannaPharmaRx over 90 days. CannaPharmaRX, Inc. operates in the cannabis industry in Canada More
CannaPharmaRx Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CannaPharmaRx's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CannaPharmaRx upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 18.02 | |||
| Information Ratio | 0.0563 | |||
| Maximum Drawdown | 105.68 | |||
| Value At Risk | (22.22) | |||
| Potential Upside | 28.57 |
CannaPharmaRx Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CannaPharmaRx's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CannaPharmaRx's standard deviation. In reality, there are many statistical measures that can use CannaPharmaRx historical prices to predict the future CannaPharmaRx's volatility.| Risk Adjusted Performance | 0.0587 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | (0.72) | |||
| Sortino Ratio | 0.0589 | |||
| Treynor Ratio | 1.57 |
CannaPharmaRx February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0587 | |||
| Market Risk Adjusted Performance | 1.58 | |||
| Mean Deviation | 10.06 | |||
| Semi Deviation | 11.28 | |||
| Downside Deviation | 18.02 | |||
| Coefficient Of Variation | 1638.87 | |||
| Standard Deviation | 18.86 | |||
| Variance | 355.88 | |||
| Information Ratio | 0.0563 | |||
| Jensen Alpha | 1.08 | |||
| Total Risk Alpha | (0.72) | |||
| Sortino Ratio | 0.0589 | |||
| Treynor Ratio | 1.57 | |||
| Maximum Drawdown | 105.68 | |||
| Value At Risk | (22.22) | |||
| Potential Upside | 28.57 | |||
| Downside Variance | 324.66 | |||
| Semi Variance | 127.34 | |||
| Expected Short fall | (25.13) | |||
| Skewness | 1.82 | |||
| Kurtosis | 7.63 |
CannaPharmaRx Backtested Returns
CannaPharmaRx is out of control given 3 months investment horizon. CannaPharmaRx secures Sharpe Ratio (or Efficiency) of 0.061, which signifies that the company had a 0.061 % return per unit of risk over the last 3 months. We have collected data for twenty-six different technical indicators, which can help you to evaluate if expected returns of 1.15% are justified by taking the suggested risk. Use CannaPharmaRx Risk Adjusted Performance of 0.0587, downside deviation of 18.02, and Mean Deviation of 10.06 to evaluate company specific risk that cannot be diversified away. CannaPharmaRx holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.73, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CannaPharmaRx's returns are expected to increase less than the market. However, during the bear market, the loss of holding CannaPharmaRx is expected to be smaller as well. Use CannaPharmaRx downside variance, day median price, and the relationship between the maximum drawdown and skewness , to analyze future returns on CannaPharmaRx.
Auto-correlation | 0.08 |
Virtually no predictability
CannaPharmaRx has virtually no predictability. Overlapping area represents the amount of predictability between CannaPharmaRx time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CannaPharmaRx price movement. The serial correlation of 0.08 indicates that barely 8.0% of current CannaPharmaRx price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.08 | |
| Spearman Rank Test | -0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CannaPharmaRx reported net income of (8.83 Million). This is 102.59% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 101.55% higher than that of the company.
CannaPharmaRx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CannaPharmaRx's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CannaPharmaRx could also be used in its relative valuation, which is a method of valuing CannaPharmaRx by comparing valuation metrics of similar companies.CannaPharmaRx is currently under evaluation in net income category among its peers.
CannaPharmaRx Fundamentals
| Return On Equity | -2.51 | |||
| Return On Asset | -0.26 | |||
| Current Valuation | 20.13 M | |||
| Shares Outstanding | 257.57 M | |||
| Shares Owned By Insiders | 1.12 % | |||
| Price To Book | 11.05 X | |||
| EBITDA | (6.07 M) | |||
| Net Income | (8.83 M) | |||
| Cash And Equivalents | 5.18 K | |||
| Total Debt | 14.96 M | |||
| Debt To Equity | 7.05 % | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (2.41 M) | |||
| Earnings Per Share | (0.12) X | |||
| Beta | 0.21 | |||
| Market Capitalization | 2.83 M | |||
| Total Asset | 114.33 K | |||
| Retained Earnings | (28.64 M) | |||
| Working Capital | (285 K) | |||
| Current Asset | 233 K | |||
| Current Liabilities | 518 K | |||
| Net Asset | 114.33 K |
About CannaPharmaRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CannaPharmaRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CannaPharmaRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CannaPharmaRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in CannaPharmaRx Pink Sheet
CannaPharmaRx financial ratios help investors to determine whether CannaPharmaRx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CannaPharmaRx with respect to the benefits of owning CannaPharmaRx security.